Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CD69 | Q07108 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sofnobrutinib SCHEMBL29547553 | 1.00 | BTK (1.00) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781705 | 0.97 | BTK (0.95) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781505 | 0.95 | BTK (0.91) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17819014 | 0.95 | BTK (0.91) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781553 | 0.95 | BTK (0.91) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781495 | 0.94 | BTK (0.88) | BTKKCNH2CD69 | |
| SCHEMBL16344057 | 0.93 | BTK (1.00) | BTKKCNH2CD69 | |
| SCHEMBL17937551 | 0.92 | BTK (0.85) | BTKKCNH2CD69 | |
| SCHEMBL17781707 | 0.92 | BTK (0.84) | BTKKCNH2CD69 | |
| SCHEMBL17819012 | 0.91 | BTK (0.83) | BTKKCNH2CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405006-A1 | COMBINATION PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | CARNA BIOSCIENCES, INC. (JP) | 2023-12-21 | — | — | US | claimed |
| US-20230100235-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2023-03-30 | — | — | US | claimed |
| EP-4101468-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences, Inc. (JP) | 2022-12-14 | — | — | EP | claimed |
| US-20240216330-A1 | COMBINATION TREATMENT METHODS OF MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216330-A1 | COMBINATION TREATMENT METHODS OF MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230405006-A1 | COMBINATION PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | CARNA BIOSCIENCES, INC. (JP) | 2023-12-21 | — | — | US | disclosed |
| WO-2023152888-A1 | FLUOROISOQUINOLINE COMPOUND AND PRODUCTION METHOD THEREOF | カルナバイオサイエンス株式会社 | 2023-08-17 | — | — | WO | disclosed |
| WO-2023152888-A1 | FLUOROISOQUINOLINE COMPOUND AND PRODUCTION METHOD THEREOF | カルナバイオサイエンス株式会社 | 2023-08-17 | — | — | WO | disclosed |
| US-20230100235-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4101468-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences, Inc. (JP) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101468-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences, Inc. (JP) | 2022-12-14 | — | — | EP | disclosed |
| EP-3026050-B1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9656995-B2 | Triazine derivative | CARNA BIOSCIENCES, INC. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9656995-B2 | Triazine derivative | CARNA BIOSCIENCES, INC. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160168122-A1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168122-A1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026050-A1 | NOVEL TRIAZINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2016-06-01 | — | — | EP | disclosed |
| EP-3026050-A1 | NOVEL TRIAZINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216330-A1 | COMBINATION TREATMENT METHODS OF MULTIPLE SCLEROSIS | BTK, FAH, SSB | BTK 1/4885KCNH2 1985/4885CD69 1732/4885 |
| US-20230405006-A1 | COMBINATION PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | BTK, PDCD1, CD274 | BTK 1/4885KCNH2 3647/4885CD69 904/4885 |
| US-20230100235-A1 | ANTICANCER AGENT COMPOSITION | BTK, MCL1, BCL2L11 | BTK 1/4885KCNH2 4308/4885CD69 2166/4885 |
| US-20160168122-A1 | NOVEL TRIAZINE DERIVATIVE | CBR3, HDAC3, SSTR3 | BTK 1313/4885KCNH2 56/4885CD69 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.